BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ambroxol readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ambroxol\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04588285-1568@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Ambroxol: Phase 2 readout est. (NCT04588285)
DESCRIPTION:Ambroxol\, phase 2.\nStudy: Ambroxol in New and Early DLB\, A P
 hase IIa Multicentre Randomized Controlled Double Blind Clinical Trial\nEs
 timated primary completion: 15 September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ambroxol#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04588285
URL:https://assetmemo.bio/drug/ambroxol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05778617-1568@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ambroxol: Phase 3 readout est. (NCT05778617)
DESCRIPTION:Ambroxol\, phase 3\, Parkinson's Disease.\nStudy: Ambroxol to S
 low Progression in Parkinson Disease\nEstimated primary completion: Februa
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ambroxol#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0577861
 7
URL:https://assetmemo.bio/drug/ambroxol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
